TABLE 1.
HR HPV positivity of the Xpert HPV versus the GP5+/6+ EIA in women presenting for routine screening in Scotland (i.e., VALGENT-2 data set) for whom outcome data were availablea
| Age and outcome | GP5+/6+ EIA result | Xpert HPV result |
||
|---|---|---|---|---|
| + | − | Total | ||
| All | ||||
| CIN2+ | + | 93 | 2 | 95 |
| − | 2 | 4 | 6 | |
| Total | 95 | 6 | 101 | |
| CIN3+ | + | 54 | 0 | 54 |
| − | 0 | 1 | 1 | |
| Total | 54 | 1 | 55 | |
| ≤CIN1 | + | 116 | 25 | 141 |
| − | 30 | 671 | 701 | |
| Total | 146 | 696 | 842 | |
| ≥30 yr | ||||
| CIN2+ | + | 36 | 1 | 37 |
| − | 2 | 2 | 4 | |
| Total | 38 | 3 | 41 | |
| CIN3+ | 23 | 0 | 23 | |
| − | 0 | 1 | 1 | |
| Total | 23 | 1 | 24 | |
| ≤CIN1 | + | 55 | 14 | 69 |
| − | 21 | 562 | 583 | |
| Total | 76 | 576 | 652 | |
Cross-tabulations are stratified according to women having CIN2+, CIN3+, or two consecutive negative cytology results and/or ≤CIN1. The top portion contains women of all ages, whereas the bottom section contains women ≥30 years of age.